Avance Biosciences™ is excited to announce that we will be exhibiting at BioProcess International and Cell & Gene Therapy International 2026, taking place January 22–25 in Boston, MA. Visit us at Booth #1402 to meet our team and discuss analytical strategies for biologics, cell therapies, gene therapies, mRNA therapeutics, and RNA vaccines.
This year, Avance Biosciences will highlight analytical services that address critical development and safety questions for advanced therapeutics, with a particular focus on analytical support for mRNA therapeutics and RNA vaccines, on/off-target analysis, biodistribution analysis, whole genome sequencing, and potency testing. Our scientists combine advanced molecular, genomic, bioanalytical, and cell-based technologies with extensive assay development, qualification, and validation experience to support programs from preclinical development through clinical trials and commercialization.
Cell-based and Potency Assay Services
Potency is a critical quality attribute for biologics, cell therapies, gene therapies, and RNA-based therapeutics. Avance Biosciences provides potency assay development, qualification, validation, and testing services designed to measure biological activity related to a product’s intended mechanism of action.
Our capabilities include cell-based potency assays, flow cytometry, ELISA, MSD, qPCR/ddPCR, and other molecular and bioanalytical approaches. We work with sponsors to develop fit-for-purpose potency strategies that can evolve alongside the product, from early development through later-stage clinical and commercial testing
Gene Editing On/Off-Target Analysis
Understanding the specificity of genome editing is an important component of evaluating the safety of gene-edited therapeutic products. Avance Biosciences provides on-target and off-target analysis services to characterize intended edits and investigate potential unintended genomic modifications.
Our NGS-based approaches support targeted and genome-wide characterization of editing outcomes, including insertions, deletions, substitutions, and other sequence alterations. These capabilities can be combined with orthogonal molecular methods and robust bioinformatics to support comprehensive gene editing safety assessments.
Whole Genome Sequencing Services
Whole genome sequencing (WGS) provides a comprehensive approach for assessing genomic characteristics that may be important to the identity, consistency, and safety of therapeutic cells and gene-edited products. Avance Biosciences offers whole genome sequencing services supported by advanced NGS instrumentation, bioinformatics, and regulatory-aligned workflows.
WGS can support evaluation of genomic integrity, single nucleotide variants, insertions and deletions, structural variants, copy number changes, and other genomic alterations. These capabilities are particularly valuable for the characterization of engineered and therapeutic cell populations where a comprehensive understanding of genomic changes may be required.
Biodistribution Studies
Biodistribution studies provide critical information about where a therapeutic product travels, persists, and clears following administration. Avance Biosciences provides biodistribution analysis using qPCR and ddPCR, enabling sensitive and quantitative detection of therapeutic nucleic acid sequences in tissues and biological matrices.
Our scientists have extensive experience developing and validating biodistribution assays for gene therapies, viral vectors, cell therapies, and other advanced therapeutic products, supporting regulated preclinical and clinical development programs.
Analytical Support for mRNA Therapeutics and RNA Vaccines
The continued development of mRNA therapeutics and RNA vaccines creates complex analytical requirements for evaluating product identity, integrity, purity, potency, and safety. Avance Biosciences provides comprehensive analytical testing support for mRNA therapeutics and RNA vaccines, including both the RNA drug substance and formulated products such as lipid nanoparticle (LNP)-based therapeutics.
Our capabilities include RNA identity and sequence confirmation, RNA integrity and purity analysis, RNA quantity, encapsulation efficiency, LNP characterization, residual impurity testing, and potency testing. Using technologies including NGS, qPCR, ddPCR, LC-MS/MS, and cell-based assays, we can develop and validate analytical methods tailored to the specific characteristics and development stage of an RNA-based product.
Meet Avance Biosciences at Booth #1402
BioProcess International and Cell & Gene Therapy International bring together scientists, developers, manufacturers, and industry leaders working to advance biologics and next-generation therapies. We look forward to meeting with attendees and discussing how Avance Biosciences can provide the analytical expertise, technologies, and regulatory-aligned testing needed to address complex development challenges.
We look forward to seeing you in Boston!
Accelerate your drug development with Avance Biosciences’ Next-Generation Sequencing (NGS) Center of Excellence, delivering GMP- and GLP-compliant genomics solutions to power your development programs. Our capabilities include Short-read Next-gen Sequencing, Nanopore Third-gen Sequencing, PacBio Third-gen Sequencing, 10X Chromium Single-cell Sequencing, and Mission Bio Tapestri Single-cell Sequencing. Learn more at our NGS Center of Excellence and contact our experts to get started.
